Monoclonal Antibodies
Fremanezumab for Preventing Migraine in Children and Adolescents
This trial is testing an injectable medication called fremanezumab to prevent migraines in children and teenagers aged 6 to 17. The medication works by blocking signals in the brain that cause headaches. Fremanezumab has been investigated for the preventive treatment of migraine in adults.
Monoclonal Antibodies
Fremanezumab for Preventing Chronic Migraine
This trial will compare the effects of a new migraine prevention drug, fremanezumab, to a placebo. The study will last 48 months and will look at safety, effectiveness, and antibody response.
Serotonin (5-HT) 1F Receptor Agonist
Lasmiditan for Pediatric Migraine
This trial is testing if lasmiditan is safe and effective for children aged 6 to 17 with migraines. The medication aims to block brain signals that cause migraine pain. The study will last several months and may include a few visits. Lasmiditan has been shown to be effective in treating acute migraine attacks in adults and is noted for its safety profile, particularly due to its lack of vasoconstrictive effects.
Popular Filters
Trials for Migraine Patients
Corticosteroid
CBT + Amitriptyline for Childhood Migraine
This trial will compare Cognitive Behavioral Therapy (CBT) via telehealth with a pill-based preventive therapy (amitriptyline) for treating childhood migraine. Results will help provide evidence-based, accessible care.
Behavioral Intervention
Mind-Body Balance for Pediatric Migraine
This trial is testing a mind-body intervention delivered by a nurse, using different doses of three treatment components, to find the combination that works best to reduce the number of headache days.
Behavioral Intervention
Online Intervention for Migraines
This trial is testing whether an online intervention can help improve headache outcomes for adolescents with migraines, compared to an attention control intervention. The primary outcome will be the number of headache days, assessed via online daily diary pre- and post-intervention.
Monoclonal Antibodies
Erenumab for Migraine
This trial tests if erenumab, an injection given regularly, can reduce migraine days in children and adolescents with chronic migraines by blocking a protein that triggers these headaches. Erenumab has been shown to reduce migraine days and improve quality of life in adults with chronic and episodic migraines.
Trials for MA Patients
Corticosteroid
CBT + Amitriptyline for Childhood Migraine
This trial will compare Cognitive Behavioral Therapy (CBT) via telehealth with a pill-based preventive therapy (amitriptyline) for treating childhood migraine. Results will help provide evidence-based, accessible care.
Behavioral Intervention
Mind-Body Balance for Pediatric Migraine
This trial is testing a mind-body intervention delivered by a nurse, using different doses of three treatment components, to find the combination that works best to reduce the number of headache days.
Behavioral Intervention
Online Intervention for Migraines
This trial is testing whether an online intervention can help improve headache outcomes for adolescents with migraines, compared to an attention control intervention. The primary outcome will be the number of headache days, assessed via online daily diary pre- and post-intervention.
Monoclonal Antibodies
Erenumab for Migraine
This trial tests if erenumab, an injection given regularly, can reduce migraine days in children and adolescents with chronic migraines by blocking a protein that triggers these headaches. Erenumab has been shown to reduce migraine days and improve quality of life in adults with chronic and episodic migraines.
Phase 3 Trials
Monoclonal Antibodies
Erenumab for Migraine
This trial tests if erenumab, an injection given regularly, can reduce migraine days in children and adolescents with chronic migraines by blocking a protein that triggers these headaches. Erenumab has been shown to reduce migraine days and improve quality of life in adults with chronic and episodic migraines.
Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist
Rimegepant for Pediatric Migraine
This trial aims to test the safety of rimegepant, a medication for treating migraines. The study focuses on children and adolescents aged 6 to 17 years who experience moderate to severe migraines. Rimegepant works by blocking a protein that triggers migraine pain, helping to alleviate symptoms.
Calcitonin Gene-Related Peptide (CGRP) Antagonist
Atogepant for Migraine Prevention
This trial is testing a medication called Atogepant to see if it can safely and effectively prevent migraines in people who have them often. The medication works by blocking signals in the brain that cause migraines. Atogepant is a newly approved oral medication for the prevention of episodic migraine.
Trials With No Placebo
Corticosteroid
CBT + Amitriptyline for Childhood Migraine
This trial will compare Cognitive Behavioral Therapy (CBT) via telehealth with a pill-based preventive therapy (amitriptyline) for treating childhood migraine. Results will help provide evidence-based, accessible care.
Behavioral Intervention
Mind-Body Balance for Pediatric Migraine
This trial is testing a mind-body intervention delivered by a nurse, using different doses of three treatment components, to find the combination that works best to reduce the number of headache days.
Behavioral Intervention
Online Intervention for Migraines
This trial is testing whether an online intervention can help improve headache outcomes for adolescents with migraines, compared to an attention control intervention. The primary outcome will be the number of headache days, assessed via online daily diary pre- and post-intervention.
Behavioural Intervention
Auricular Acupuncture for Migraines
This trial compares ear acupuncture and standard IV medications for treating migraines in children in the emergency room. Ear acupuncture uses needles in the ear to change nerve signals and reduce pain, while standard treatments use drugs to relieve symptoms.
Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist
Rimegepant for Pediatric Migraine
This trial aims to test the safety of rimegepant, a medication for treating migraines. The study focuses on children and adolescents aged 6 to 17 years who experience moderate to severe migraines. Rimegepant works by blocking a protein that triggers migraine pain, helping to alleviate symptoms.
View More Related Trials
Frequently Asked Questions
Introduction to migraine headaches
What are the top hospitals conducting migraine headaches research?
For those living with the debilitating effects of migraine headaches, finding relief can often be a challenging journey. However, several hospitals across the United States are diligently working to change that narrative through their commitment to cutting-edge clinical trials. In Bellevue, Washington, Northwest Clinical Research Center takes the lead with an impressive 12 ongoing migraine headaches trials and a cumulative total of 37 studies dedicated to understanding this condition. Since recording its first trial in 2014, this research center has been at the forefront of advancements in migraine treatment.
Meanwhile, Clinvest Research LLC in Springfield is making significant strides as well. With nine active migraine headaches trials and a history encompassing 17 previous studies since their initial trial in 2018, they are actively seeking new solutions for those plagued by migraines.
In another part of Ohio lies Cincinnati Children's Hospital Medical Center which is playing a crucial role in unraveling the mysteries surrounding migraines. This renowned hospital currently hosts eight active clinical trials centered around migraines while having conducted an additional thirteen studies since embarking on their first trial back in 2012.
Boston also houses one such institution devoted to pioneering migraine research: Boston Clinical Trials. With eight ongoing clinical tests aimed at alleviating these severe headaches and twenty-three previously completed investigations dating back to their inaugural study in 2015; they too remain steadfastly committed towards advancing our understanding of this condition.
Finally joining forces in Stamford Connecticut would be New England Institute for Clinical Research where seven present-day experiments continue evaluating potential treatments while simultaneously striving forward using insights accumulated throughout sixteen past explorations from starting out into possible remedies just about ten years ago during2012
These hospitals' dedication underscores not only the severity and complexity of migraines but also serves as a beacon of hope for sufferers worldwide who yearn for effective relief options. The collective efforts made by these leading institutions remind us that every breakthrough achieved through rigorous research brings us closer to providing much-needed respite to those burdened by the throbbing pain of migraines.
Which are the best cities for migraine headaches clinical trials?
When it comes to clinical trials for migraine headaches, several cities stand out as hubs of research and development. Miami, Florida leads the pack with 45 active trials focusing on medications like Lasmiditan, Ubrogepant, and Rimegepant/BHV3000. Cincinnati, Ohio follows closely behind with 37 ongoing studies investigating treatments such as Rimegepant/BHV3000, Ubrogepant, and Fremanezumab. Additionally, Dallas in Texas offers 26 active trials exploring potential solutions like Ubrogepant, Fremanezumab, and Atogepant 60 mg. These cities provide individuals suffering from migraines access to cutting-edge clinical trials that pave the way for advanced treatments and improved quality of life.
Which are the top treatments for migraine headaches being explored in clinical trials?
Migraine headaches, a common and debilitating condition, are the focus of ongoing clinical trials exploring innovative treatments. Leading the pack is fremanezumab, currently involved in three active trials and contributing to 13 all-time studies dedicated to migraine headaches since its introduction in 2016. Not far behind is eptinezumab, making waves with three active trials and participating in 12 all-time studies since its debut in 2019. In addition to pharmaceutical approaches, emotional awareness and expression therapy (EAET) has also emerged as a contender with two active trials focusing on this novel treatment method that was first listed for study in 2023. Also showing promise are erenumab dose 3 and galcanezumab, both engaged in two active trials each while accumulating valuable data from previous research endeavors. With these exciting developments underway, hope remains high for finding effective solutions to alleviate the burden of migraine headaches on those affected by this condition.
What are the most recent clinical trials for migraine headaches?
Recent clinical trials have brought new hope for individuals suffering from migraine headaches. Among these trials are studies on atogepant, a potential treatment that has entered Phase 3 and shows promise in managing migraines. Another notable trial is the ReMMiD-C Therapeutic Arm A study, also in Phase 3, which investigates a therapeutic approach specifically designed for migraine headaches. Additionally, research on greater occipital nerve block groups aims to explore innovative methods to alleviate the symptoms of migraines. These breakthroughs provide optimism for improved management and relief for those affected by this debilitating condition.
What migraine headaches clinical trials were recently completed?
Several recent clinical trials have made significant progress in the field of migraine headache treatment. In March 2022, a trial sponsored by Allergan concluded its investigation into Ubrogepant's efficacy for managing migraines. Similarly, Eli Lilly and Company completed a trial on Galcanezumab in December 2021, while H. Lundbeck A/S finalized their study on Lu AG09222 in November of the same year. Additionally, Satsuma Pharmaceuticals' investigation of Dihydroergotamine wrapped up in June 2021. These important advancements underscore ongoing efforts to develop effective therapies for individuals suffering from debilitating migraine headaches.